BACKGROUND: Low lymphocyte count is a prognostic factor in cancer patients including metastatic breast cancer patients (MBC) but the relative role of each lymphocyte subtype is unclear in MBC. METHODS: The impact of lymphocyte subsets was analysed in two prospective MBC patients' cohorts. Cohort A patients (n=103) were included before the first line of chemotherapy and cohort B patients (n=101) were included after at least one line of chemotherapy. Extensive phenotypic analyses were performed on fresh whole blood. Plasma cytokines levels were measured using commercially available Luminex-based multiplex kits. Prognostic value of lymphocyte subsets and circulating cytokines was analysed. RESULTS: In both cohorts, severe lymphopaenia (<0.7 Giga/L) correlated with poor overall survival (OS) (median OS: 6.6 months versus 21.7 months in cohort A and 4.5 versus 9 months in cohort B). CD8(+), CD19(+) and CD56(+) T cell counts had no significant prognostic value for OS. After stratification (≤0.2, [0.20-0.45], >0.45 Giga/L), CD4 lymphopaenia appeared to be correlated with poor OS in both cohorts. Furthermore, severe CD4(+) lymphopaenia (≤0.2 Giga/L) was strongly correlated with poor OS in both cohorts (1.2 months versus 24.9 months in cohort A and 5.7 versus 13.1 months in cohort B). In multivariate analysis, after stratification CD4(+) lymphopaenia appeared to be an independent prognostic factor for OS in both cohorts. CD4(+) lymphopaenia correlated with low plasmatic levels of CCL22 that might directly contribute to CD4(+) lymphopaenia. CONCLUSIONS: CD4(+) lymphopaenia was associated with reduced OS in MBC patients regardless of the chemotherapy line. Decreased levels of plasmatic CCL22 may contribute to CD4(+) lymphopaenia.
BACKGROUND: Low lymphocyte count is a prognostic factor in cancerpatients including metastatic breast cancerpatients (MBC) but the relative role of each lymphocyte subtype is unclear in MBC. METHODS: The impact of lymphocyte subsets was analysed in two prospective MBCpatients' cohorts. Cohort A patients (n=103) were included before the first line of chemotherapy and cohort B patients (n=101) were included after at least one line of chemotherapy. Extensive phenotypic analyses were performed on fresh whole blood. Plasma cytokines levels were measured using commercially available Luminex-based multiplex kits. Prognostic value of lymphocyte subsets and circulating cytokines was analysed. RESULTS: In both cohorts, severe lymphopaenia (<0.7 Giga/L) correlated with poor overall survival (OS) (median OS: 6.6 months versus 21.7 months in cohort A and 4.5 versus 9 months in cohort B). CD8(+), CD19(+) and CD56(+) T cell counts had no significant prognostic value for OS. After stratification (≤0.2, [0.20-0.45], >0.45 Giga/L), CD4 lymphopaenia appeared to be correlated with poor OS in both cohorts. Furthermore, severe CD4(+) lymphopaenia (≤0.2 Giga/L) was strongly correlated with poor OS in both cohorts (1.2 months versus 24.9 months in cohort A and 5.7 versus 13.1 months in cohort B). In multivariate analysis, after stratification CD4(+) lymphopaenia appeared to be an independent prognostic factor for OS in both cohorts. CD4(+) lymphopaenia correlated with low plasmatic levels of CCL22 that might directly contribute to CD4(+) lymphopaenia. CONCLUSIONS:CD4(+) lymphopaenia was associated with reduced OS in MBCpatients regardless of the chemotherapy line. Decreased levels of plasmatic CCL22 may contribute to CD4(+) lymphopaenia.
Authors: John K Wiencke; Paige M Bracci; George Hsuang; Shichun Zheng; Helen Hansen; Margaret R Wrensch; Terri Rice; Melissa Eliot; Karl T Kelsey Journal: Epigenetics Date: 2014-10 Impact factor: 4.528
Authors: Lisa D Mills; Lizhi Zhang; Ronald Marler; Phyllis Svingen; Maite G Fernandez-Barrena; Maneesh Dave; William Bamlet; Robert R McWilliams; Gloria M Petersen; William Faubion; Martin E Fernandez-Zapico Journal: J Biol Chem Date: 2014-04-15 Impact factor: 5.157
Authors: Mi Zhou; Paige M Bracci; Lucie S McCoy; George Hsuang; Joseph L Wiemels; Terri Rice; Shichun Zheng; Karl T Kelsey; Margaret R Wrensch; John K Wiencke Journal: Int J Cancer Date: 2015-02-02 Impact factor: 7.316
Authors: Elena García-Martínez; Ginés Luengo Gil; Asunción Chaves Benito; Enrique González-Billalabeitia; María Angeles Vicente Conesa; Teresa García García; Elisa García-Garre; Vicente Vicente; Francisco Ayala de la Peña Journal: Breast Cancer Res Date: 2014-11-29 Impact factor: 6.466
Authors: E Verronèse; A Delgado; J Valladeau-Guilemond; G Garin; S Guillemaut; O Tredan; I Ray-Coquard; T Bachelot; A N'Kodia; C Bardin-Dit-Courageot; C Rigal; D Pérol; C Caux; C Ménétrier-Caux Journal: Oncoimmunology Date: 2015-11-10 Impact factor: 8.110